Researchers are also conducting clinical trials to test other types of IDH inhibitors, other targeted therapies, and immunotherapies for treating certain types of IDH-mutant gliomas. Read on to ...

Isocitrate dehydrogenase (IDH)–mutant grade 2 gliomas are malignant ... to detect a hazard ratio of 0.6 with the use of a log-rank test at a one-sided significance level of 0.025.

In a study published in Nature Communications, researchers introduce a blood-based test, mt-IDHI dx ... based assay for the detection of IDH1.R132H-mutant gliomas, Nature Communications (2024).

INDIGO was a phase 3 trial that included 331 adult patients (median age, 40.5 years) with grade 2 IDH-mutant recurrent or residual glioma after surgery. To be eligible, patients had to be followed ...

Somatic monoallelic single nucleotide variants in the genes that encode isocitrate dehydrogenase (IDH) 1 and 2 are found in a large subset of diffusely infiltrating gliomas and subsets of acute ...

Oncomine Dx Target Test to Identify Patients Eligible for Servier’s VORANIGO® (vorasidenib) tablet, the only FDA-approved treatment for Grade 2 IDH-mutant glioma CARLSBAD, Calif., October 21 ...

3 "Patients living with Grade 2 IDH-mutant gliomas must contend with a grim prognosis that has few options outside of surgery. This is a devastating diagnosis, particularly for individuals in ...

As the FDA noted in its press release, this marks the first approval of a systemic therapy for this type of grade 2 IDH-mutant brain cancer, which includes oligodendrogliomas and astrocytomas.

HOUSTON -- Progression-free survival (PFS) in IDH-mutant low-grade glioma remained twice as high in adults who received vorasidenib (Voranigo) after surgery versus placebo, according to a follow ...

Importantly, the FDA approved a drug (vorasidenib) for this mutation in glioma in August 2024—this means that the test ... assay for the detection of IDH1.R132H-mutant gliomas, Nature ...